跳到正文
原文
STAT Pharma 医药频道· Meghana Keshavan·· 2026-10-15AI 评分17

Verastem的KRAS抑制剂在胰腺癌中显示潜力

STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer

AI 导读

Verastem开发的KRAS抑制剂在胰腺癌患者中表现出疗效潜力。该结果源自STAT+独家报道,但全文因订阅限制未在此处完整展示。

正文

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

I, too, wanted to express how devastated I am over losing our colleague Helen Branswell.  She was kind, scrupulous, brilliant, and truly inspiring in action. Thank you, Helen. 

The need-to-know this morning

  • Privately held U.K. biotech OMass Therapeutics raised $310 million to support the clinical development of a drug to treat congenital adrenal hyperplasia, an inherited endocrine disorder. 
  • The investment firm Orbimed raised nearly $3 billion for two, new private equity funds that will invest in U.S, European and Asian health care companies. 

Investor: China’s biotech boom threatens U.S. venture capital

From STAT’s Allison DeAngelis: The rise of Chinese biotech isn’t just impacting U.S. companies, one investor is warning. It’s threatening VC firms.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT Pharma 医药频道 · statnews.com